Clinical Trials
23 trialsNCT03437941 2026-05-15
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
Phase 1/2 Terminated
NCT07190300 2026-05-12
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT06764485 2026-05-06
rechARge
Celgene
Phase 3 Recruiting
NCT07336446 2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2 Recruiting
NCT05694819 2026-04-08
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Completed
NCT06365788 2026-04-01
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT04090528 2025-12-05
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT02294461 2025-10-24
An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
Astellas Pharma Inc
Phase 3 Completed
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT05241613 2025-02-13
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Accutar Biotechnology Inc
Phase 1 Terminated
NCT01969578 2024-11-05
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04869943 2024-01-26
ARTEST
Veru Inc.
Phase 3 Terminated
NCT05673109 2024-01-25
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Accutar Biotechnology Inc
Phase 1 Terminated
NCT03050866 2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2 Unknown
NCT03478904 2021-05-10
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02162836 2020-04-27
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT00878436 2018-02-07
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
NYU Langone Health
Phase 1/2 Completed
NCT02348281 2018-01-23
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Fudan University
Phase 2 Terminated
NCT02910050 2017-12-22
BETTER
Sun Yat-sen University
Phase 2 Unknown
NCT00365599 2014-11-21
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00918385 2014-10-29
ARS
Duke University
Phase 2 Terminated
NCT01351688 2013-07-03
An Open Label Prostate Cancer Study in Japanese Patients
AstraZeneca
Phase 1 Completed
NCT01337518 2012-12-18
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Enzon Pharmaceuticals, Inc.
Phase 1 Suspended